hrp0097p1-99 | GH and IGFs | ESPE2023

Clinicians’ perceptions on ease of use and usefulness of Aluetta® Smartdot™ and comprehensive digital health ecosystem in Italy to support patients receiving r-hGH treatment

Felicia Faienza Maria , Vergani Edoardo , Di Mase Raffaella , Frasca Francesco , Giavoli Claudia , Klain Antonella , Laura Iezzi Maria , Aversa Antonio , Koledova Ekaterina , Rivera Romero Octavio

Background: Aluetta® Smartdot™ (Merck Healthcare KGaA, Darmstadt, Germany) is first of its kind digitally connected smart injection pen device for recombinant-human growth hormone (r-hGH) administration. Aluetta® pen with Smartdot™ knob attachment integrated with Growzen™ digital ecosystem enables healthcare professionals (HCPs) to remotely monitor adherence and achieve optimal clinical outcomes for patients....

hrp0098p2-265 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2024

Gonadal function and outcome in 46, XX testicular/ovotesticular DSD – first round collection data from the I-DSD Registry study.

Sepich Margherita , Bertelloni Silvano , Tyutyusheva Nina , Lucas-Herald Angela , Mazen Inas , Cools Martine , Poyrazoğlu Şükran , Hiort Olaf , Döhnert Ulla , Neumann Uta , Phan-Hug Franziska , Atapattu Navoda , Nimali Seneviratne Sumudu , Markosyan Renata , Suco Sofía , Baronio Federico , Lichiardopol Corina , Verkauskas Gilvydas , Rita Stancampiano Marianna , Russo Gianni , Konrad Daniel , Lenherr-Taube Nina , E Hannema Sabine , Thankamony Ajay , Gazdagh Gabriella , G Peroni Diego , Faisal Ahmed S

Background: Testicular and ovo-testicular 46,XX-DSD are very rare conditions that have a variable presentation and often pose challenging questions regarding long-term outcome of gonadal function.Methods: Eligible cases were identified in the I-DSD Registry and centres were asked to update the clinical dataset to their last available assessment. The cases were categorised by assigned sex and age categories. Elevated and ...

hrp0097p1-574 | Sex Differentiation, Gonads and Gynaecology, and Sex Endocrinology | ESPE2023

Gonadal histopathology in 17beta-HSD deficiency and 5alpha-reductase deficiency

Boogers L.S. , Brüggenwirth H.T. , van Bever Y. , Hersmus R. , Bryce J. , Ahmed S.F. , Lucas-Herald A.K. , Baronio F. , Cools M. , Ellaithi M. , Globa E. , Güran T. , Hiort O. , Holterhus P.M. , MсElreavey K. , Niedziela M. , Stancampiano M.R. , Tosun B.G. , Wolffenbuttel K.P. , Oosterhuis J.W. , Looijenga L.H.J. , Hannema S.E.

Introduction: In various forms of XY disorders/differences of sex development (DSD) the risk of germ cell cancer is increased. In the 2006 DSD consensus statement this risk was estimated to be intermediate in 17beta-HSDtype3 deficiency (HSD17B3D) and low in 5alpha-reductasetype2 deficiency (SRD5A2D) but based on very few cases. Few studies have been performed since; therefore we aimed to review gonadal pathology in an international cohort with these conditions...

hrp0097p1-238 | Diabetes and Insulin | ESPE2023

MiniMed 780G Advanced Hybrid Closed Loop System Outcomes According to Pubertal Status - Awesome Study Group Real-Life Experience

Rachmiel Marianna , Lebenthal Yael , Kineret Mazor-Aronovitch Kineret , Brener Avivit , Levek Noah , Polishuk-Yakobi Talia , Tal Ben Tal , Abiri Shirli , Landau Zohar , Pinhas-Hamiel Orit

Background and aims: Achieving good glycemic control is a major challenge for adolescents with type 1 diabetes (TID). The introduction of the MiniMed 780G system, an advanced hybrid closed-loop (AHCL), that enables an automatic correction of insulin, gave hope for improved glycemic outcomes in adolescents. We assessed specific characteristics associated with glycemic measures in youth with T1D switching to Minimed 780G.Methods:</...

hrp0095fc6.3 | Sex Development and Gonads | ESPE2022

Gonadal morphology in 46,XY gonadal dysgenesis: I-DSD Registry-based study

Tadokoro-Cuccaro Rieko , Hughes Ieuan , Cools Martine , van de Vijver Koen , Bilharinho de Mendonça Berenice , Domenice Sorahia , L Batista Rafael , Thomazini Dallago Renata , Lisboa Gomes Nathalia , Costa Elaine F. , Maciel-Guerra Andréa T. , Guerra-Junior Gil , Gabriel Ribeiro de Andrade Juliana , Lucas-Herald Angela , Bryce Jillian , Hannema Sabine , Juul Anders , Globa Eugenia , MсElreavey Kenneth , Baronio Federico , Lopez Dacal Jimena , Darendeliler Feyza , Poyrazoglu Sukran , Kolesińska Zofia , Niedziela Marek , Claahsen – van der Grinten Hedi L. , van den Akke Erica L.T. , Herrmann Gloria , Atapattu Navoda , Jain Vandana , Sharma Rajni , Bettendorf Markus , Konrad Daniel , Martin Holterhus Paul , Fica Simona , Skae Mars , Russo Gianni , Rita Stancampiano Marianna , Gazdagh Gabriella , H Davies Justin , Mohamed Zainaba , Nimali Seneviratne Sumudu , Guran Tulay , GÜVEN Ayla , Wasniewska Malgorzata , Mladenov Vilhelm , Verkauskas Gilvydas , Markosyan Renata , Korbonits Marta , Faisal Ahmed S , Hiort Olaf , Wagner Isabel , Thankamony Ajay

Background/Aims: 46,XY gonadal dysgenesis (GD) is classified as complete (CGD) or partial (PGD) depending on gonadal morphology and function. In contrast to the typical female external genitalia in CGD, the phenotype of PGD is variable depending on androgen production. A diagnosis of PGD is based on clinical/biochemical features, gonadal histology and genetic findings. The aim of this study is to characterise these features, particularly histological, in a lar...

hrp0095p1-555 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Management Options for Adolescents with Abnormal Uterine Bleeding, according to their Demographic, Clinical and Laboratory Characteristics.

Keidar Noa , Smorgick Noam , Rachmiel Marianna

Background: Abnormal uterine bleeding is a common complaint among adolescents, however, there are no evidence-based guidelines for their treatment, and there is a paucity of outcome data available.Objectives: To describe the characteristics of adolescents with menstrual abnormalities and to describe management protocol outcomes.Methods: This is a retrospective study, based on infor...

hrp0094p2-90 | Bone, growth plate and mineral metabolism | ESPE2021

Changing reality: rebirth of old diseases in new circumstances. Severe vitamin D deficiency presenting as hypocalcemic seizures in a healthy adolescent after prolonged COVID-19 lock-down.

Naugolny Larissa , Rachmiel Marianna , Weintrob Naomi ,

Context: Nutritional vitamin D deficiency is rare in the high income countries; its manifestations are usually associated with the combination of accompanying risk factors, as malnutrition, chronic illness, dark skin or restricted exposure to sunlight due to cultural practices.Objective: The aim of this case report is to increase the awareness to severe vitamin D deficiency as a result of extreme indoor isolation due to ...

hrp0097lb13 | Late Breaking | ESPE2023

Low-Dose Liraglutide-Induced Acute Kidney Injury and Hepatocellular Disorder in an Adolescent Patient

Wittenberg Avigail , Komargodski Rinat , Rachmiel Marianna

Background: Liraglutide (SAXENDA®) is a glucagon-like peptide 1 (GLP-1) receptor agonist approved as an adjunct for chronic weight management in combination with a reduced-calorie diet and increased physical activity. Previous case reports have suggested an association between liraglutide use and acute kidney injury in adults, particularly at maintenance doses of 1.2 mg/day or higher. However, there is less data on the impact of liraglutide in the adolesce...

hrp0084fc8.5 | Obesity - Basic | ESPE2015

Adipocytokines in Placenta and Cord Blood in Relation to Maternal Obesity, and Foetal and Postnatal Growth of the Child

Allbrand Marianne , AEman Jan , Lodefalk Maria

Background: The nutritional and hormonal state in utero may be a link between maternal obesity and obesity in the offspring. The gene expression in placentae in pregnancies complicated by diabetes is reduced for leptin, but increased for ghrelin. It is not known whether these genes’ expressions in placentae are altered in maternal obesity.Objectives and hypotheses: To compare obese and normal-weight women and their children concerning gene ...

hrp0098p2-227 | Pituitary, Neuroendocrinology and Puberty | ESPE2024

Real Life Efficacy and Safety of Monthly (4-week) and 6-Monthly (24-week) Formulations of Gonadotropin-Releasing Hormone Agonist (GnRHa) Among Children with Central Precocious and Early Fast Puberty

Shopen Libby , Dror Nitzan , Eliakim Alon , Rachmiel Marianna , Barash Galia

Background: Central precocious puberty (CPP), early fast puberty (EFP) and early puberty (EP) are considered as deviations from normal variability of pubertal tempo. Gonadotropin releasing hormone agonists (GnRHa) have been considered the treatment of choice for CPP for decades, and later for EFP. Several pharmaceutical formulations of GnRHa have been developed, differing in the route and frequency of administration. Treatment was administered mainly by intra-...